MA30991B1 - Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 - Google Patents

Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4

Info

Publication number
MA30991B1
MA30991B1 MA31990A MA31990A MA30991B1 MA 30991 B1 MA30991 B1 MA 30991B1 MA 31990 A MA31990 A MA 31990A MA 31990 A MA31990 A MA 31990A MA 30991 B1 MA30991 B1 MA 30991B1
Authority
MA
Morocco
Prior art keywords
agonists
receptors
benzamide derivatives
compounds
benzamide
Prior art date
Application number
MA31990A
Other languages
English (en)
Inventor
Alessandra Gaiba
Mark Patrick Healy
Christopher Norbert Johnson
Susan Roomans
Steven James Stanway
Martin Edward Swarbrick
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0625098A external-priority patent/GB0625098D0/en
Priority claimed from GB0715145A external-priority patent/GB0715145D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30991B1 publication Critical patent/MA30991B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/56Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

CETTE INVENTION CONCERNE UN COMPOSÉ DE FORMULE (I) OU SON DÉRIVÉ PHARMACEUTIQUEMENT ACCEPTABLE, OÙ R1, R2, R3, R4, R5, M, N ET X SONT TELS QUE DÉFINIS DANS LE MÉMOIRE. L'INVENTION DÉCRIT ÉGALEMENT UN PROCÉDÉ PERMETTANT DE PRÉPARER DE TELS COMPOSÉS, UNE COMPOSITION PHARMACEUTIQUE COMPRENANT CES COMPOSÉS, AINSI QUE L'UTILISATION PHARMACOLOGIQUE DE CES COMPOSÉS.
MA31990A 2006-12-15 2009-06-15 Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4 MA30991B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0625098A GB0625098D0 (en) 2006-12-15 2006-12-15 Novel compounds
GB0715145A GB0715145D0 (en) 2007-08-03 2007-08-03 Novel compounds

Publications (1)

Publication Number Publication Date
MA30991B1 true MA30991B1 (fr) 2009-12-01

Family

ID=39149241

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31990A MA30991B1 (fr) 2006-12-15 2009-06-15 Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4

Country Status (21)

Country Link
US (3) US20080167377A1 (fr)
EP (1) EP2101751A1 (fr)
JP (1) JP5069752B2 (fr)
KR (1) KR20090089868A (fr)
AR (1) AR064361A1 (fr)
AU (1) AU2007331471C1 (fr)
BR (1) BRPI0720254A2 (fr)
CA (1) CA2672631A1 (fr)
CL (1) CL2007003640A1 (fr)
CR (1) CR10849A (fr)
DO (1) DOP2009000124A (fr)
EA (1) EA015931B1 (fr)
IL (1) IL198931A0 (fr)
MA (1) MA30991B1 (fr)
MX (1) MX2009006474A (fr)
NO (1) NO20092314L (fr)
NZ (1) NZ577109A (fr)
PE (1) PE20081579A1 (fr)
SG (1) SG177203A1 (fr)
TW (1) TW200848014A (fr)
WO (1) WO2008071736A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172447A4 (fr) * 2007-07-03 2011-08-24 Astellas Pharma Inc Composé amide
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CA2707789A1 (fr) * 2007-12-19 2009-07-09 Amgen Inc. Derives de l'acide phenylacetique utiles comme modulateurs de l'inflammation
EP2565191B1 (fr) 2008-05-14 2014-10-08 Astellas Pharma Inc. Dérivés d'acide 4-(indol-7-ylcarbonylaminométhyl)cyclohexanecarboxylique comme antagonistes du récepteur EP4 utilisables pour le traitement de l'insuffisance rénale chronique ou de la néphropathie diabétique
GB0810313D0 (en) * 2008-06-05 2008-07-09 Glaxo Group Ltd Novel compounds
GB0810617D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
GB0810615D0 (en) * 2008-06-10 2008-07-16 Glaxo Group Ltd Novel pharmaceutical
ES2512727T3 (es) * 2009-09-29 2014-10-24 Glaxo Group Limited Nuevos compuestos
CN102596921B (zh) * 2009-09-29 2015-04-29 葛兰素集团有限公司 新化合物
US20120190637A1 (en) 2009-10-14 2012-07-26 Gemmus Pharma, Inc. Combination therapy treatment for viral infections
WO2012016109A2 (fr) * 2010-07-30 2012-02-02 Allergan, Inc. Composés et procédés destinés à la réparation de la peau
US8900571B2 (en) 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8926963B2 (en) 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
CN103097358B (zh) 2010-09-21 2015-04-08 卫材R&D管理有限公司 药物组合物
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
EP2814527A1 (fr) * 2012-02-16 2014-12-24 Allergan, Inc. Compositions et procédés perfectionnés de remplacement de tissu mou
EP2765128A1 (fr) * 2013-02-07 2014-08-13 Almirall, S.A. Benzamides substitués présentant une activité vis-à-vis de récepteurs EP4
NZ717739A (en) 2013-08-09 2023-12-22 Ardelyx Inc Compounds and methods for inhibiting phosphate transport
NZ733234A (en) * 2014-03-06 2018-08-31 Aratana Therapeutics Inc Crystalline forms of grapiprant
EP3245186A1 (fr) 2015-01-16 2017-11-22 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Procédé de préparation de composés phénoliques à partir de biomasse
EP3184505A1 (fr) 2015-12-22 2017-06-28 Nederlandse Organisatie voor toegepast- natuurwetenschappelijk onderzoek TNO Procédé de préparation de composés phénoliques à l'aide d'un catalyseur
CN113905732A (zh) * 2019-04-09 2022-01-07 纽罗比特科学有限公司 用于预防或治疗脊髓损伤或椎管狭窄的药物组合物
US20200368223A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Methods for inhibiting phosphate transport
CN111454150B (zh) * 2019-12-25 2023-03-28 南京工业大学 一种(s)-2-芳基丙酸酯类化合物的合成方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd 3,7−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
AUPO713297A0 (en) 1997-06-02 1997-06-26 Fujisawa Pharmaceutical Co., Ltd. Oxazole compound
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
TWI249520B (en) 1998-07-15 2006-02-21 Ono Pharmaceutical Co 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient
US6586468B1 (en) 1998-09-14 2003-07-01 Ono Pharmaceutical Co., Ltd. ω-substituted phenyl-prostaglandin E derivatives and drugs containing the same as the active ingredient
AUPP608898A0 (en) 1998-09-23 1998-10-15 Fujisawa Pharmaceutical Co., Ltd. New use of prostaglandin E2 antagonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
WO2000021532A1 (fr) 1998-10-15 2000-04-20 Merck & Co., Inc. Inhibition de la resorption osseuse
GB0031295D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Naphthalene derivatives
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
GB0031315D0 (en) 2000-12-21 2001-02-07 Glaxo Group Ltd Indole derivatives
GB0103269D0 (en) 2001-02-09 2001-03-28 Glaxo Group Ltd Napthalene derivatives
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
EP1487437B1 (fr) 2002-03-18 2006-08-16 Pfizer Products Inc. Utilisation d'agonistes selectifs du recepteur ep4 pour le traitement de maladies
EP1499305A2 (fr) 2002-04-12 2005-01-26 Pfizer Japan Inc. Utilisation de ligands du recepteur ep4 dans le traitement de maladies impliquant il-6
EP1556347A4 (fr) 2002-06-10 2006-08-09 Applied Research Systems Gamma lactames utilises en tant qu'agonistes de la prostaglandine et leur utilisation
AU2003275838A1 (en) 2002-10-25 2004-05-13 Beunard, Jean-Luc Pyrrolidin-2-on derivatives as ep4 receptor agonists
US7053085B2 (en) 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
CA2511255C (fr) 2003-01-10 2009-04-07 F. Hoffmann-La Roche Ag Derives de 2-piperidone agonistes de la prostaglandine
CN100408570C (zh) 2003-01-29 2008-08-06 阿斯特兰德英国有限公司 Ep4受体拮抗剂
EP1663979B1 (fr) 2003-09-03 2013-10-09 RaQualia Pharma Inc. Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2
GB0324269D0 (en) 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
WO2005080367A1 (fr) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Agonistes des recepteurs ep2
CN1950333A (zh) 2004-05-04 2007-04-18 辉瑞大药厂 取代的甲基芳基或杂芳基酰胺化合物
WO2005105733A1 (fr) * 2004-05-04 2005-11-10 Pfizer Japan Inc. Composes aryl- ou heteroarylamides ortho-substitues
WO2005116010A1 (fr) 2004-05-26 2005-12-08 Merck Frosst Canada Ltd. Agoniste du recepteur ep4, compositions et methodes associees ep4 receptor agonist, compositions and methods thereof
ATE533766T1 (de) 2005-05-19 2011-12-15 Merck Canada Inc Chinolinderivate als ep4-antagonisten

Also Published As

Publication number Publication date
DOP2009000124A (es) 2010-03-31
TW200848014A (en) 2008-12-16
US20130261185A1 (en) 2013-10-03
NO20092314L (no) 2009-08-31
US8314147B2 (en) 2012-11-20
EA015931B1 (ru) 2011-12-30
CA2672631A1 (fr) 2008-06-19
JP2010513242A (ja) 2010-04-30
SG177203A1 (en) 2012-01-30
CR10849A (es) 2009-08-12
MX2009006474A (es) 2009-06-26
BRPI0720254A2 (pt) 2014-01-07
US20100022650A1 (en) 2010-01-28
US20080167377A1 (en) 2008-07-10
WO2008071736A1 (fr) 2008-06-19
CL2007003640A1 (es) 2008-07-11
AU2007331471C1 (en) 2013-07-25
IL198931A0 (en) 2010-02-17
NZ577109A (en) 2011-12-22
AR064361A1 (es) 2009-04-01
AU2007331471A1 (en) 2008-06-19
AU2007331471B2 (en) 2013-01-10
JP5069752B2 (ja) 2012-11-07
KR20090089868A (ko) 2009-08-24
EP2101751A1 (fr) 2009-09-23
EA200970585A1 (ru) 2009-10-30
PE20081579A1 (es) 2009-01-01

Similar Documents

Publication Publication Date Title
MA30991B1 (fr) Utilisation de dérivés du benzamide comme agonistes des récepteurs ep4
MA33636B1 (fr) Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine
MA31988B1 (fr) Derives d'aminopyrazole
MA31084B1 (fr) Derives de piperidine agonistes de gpcr
MA38325A3 (fr) Dérivés de benzothiophène et compositions correspondantes en tant qu'agents de dégradation sélectifs des récepteurs des œstrogènes
MA34361B1 (fr) Dérivés de tétrahydro-pyrido-pyrimidine
EA200501585A1 (ru) Производные азетидинкарбоксамида и их применение при лечении нарушений, опосредованных св1 рецепторами
MA34300B1 (fr) Composés azotés hétérocycliques convenant comme inhibiteurs de la pde10
MA29772B1 (fr) Benzimidazoles substitues et procedes de preparation
MA32231B1 (fr) Composés organiques
TNSN08270A1 (fr) Dérivés pyrimidiques destinés à traiter une croissance cellulaire anormale
MA30717B1 (fr) Derives de pyridin-3-yle en tant qu'agents immunomodulateurs
MA30718B1 (fr) Derives de pyridin-4-yle en tant qu'agents immunomodulateurs.
MA29170B1 (fr) Derives puriniques agissant comme des agonistes du recepteur a2a
MA29335B1 (fr) Derives de n-(n-sulfonylaminomethyl) cyclopropanecarboxamide utiles pour le traitement de la douleur
TW200719886A (en) Dihydrobenzofuran derivatives and uses thereof
MA32104B1 (fr) Dérivés d'oxime en tant qu'inhibiteurs de hsp90
MA31593B1 (fr) Derives de 2-aza-bicyclo[3.3.0]octane
MA30284B1 (fr) Composes de 8-azabicyclo[3.2.1]octane en tant qu'antagonistes du recepteur opioide mu
MA30166B1 (fr) Imidazoles substitues et leur utilisation comme pesticides.
ZA202306748B (en) Glp-1r receptor agonist compound and use thereof
MA30696B1 (fr) Derives de l'acide (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetique
MA31521B1 (fr) Dérivés de 2,3-dihydrobenzo[1,4] dioxin-2-ylméthyle utilisés en tant qu'antagonistes des alpha2c pour traiter des maladies des systèmes nerveux périphérique et central
MA33132B1 (fr) Derives pyrazole utilises comme antagonistes du recepteur ccr4
MA31699B1 (fr) Dérivés d'isoquinolinyle et d'isoindolinyle servant d'antagonistes du récepteur d'histamine-3